Homepage
Author:
Nuvation Bio, Inc.
Posted Date:
April 1, 2026
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
Nuvation Bio, Inc.
April 1, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Nuvation Bio, Inc.
March 26, 2026
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Nuvation Bio, Inc.
March 17, 2026
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Nuvation Bio, Inc.
March 2, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio, Inc.
February 25, 2026
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
Nuvation Bio, Inc.
February 17, 2026
